The genetics of Adamantiades-Behcet's disease

Seminars in Ophthalmology

Volumn 23, Issue 1, 2008, Pages 73-79

  Durrani, K ^a   Papaliodis, G N ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

Adamantiades Behcet's Disease; Behcet's Disease; Iritis; Uveitis; Vasculitis

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HLA B51 ANTIGEN;

ADAMANTIADES BEHCET DISEASE; ANTERIOR EYE CHAMBER; ARTHRITIS; BLINDNESS; CLINICAL FEATURE; DIAGNOSTIC TEST; DIGESTIVE SYSTEM INJURY; ENVIRONMENTAL FACTOR; EYE INJURY; GENETIC DISORDER; GENETIC SUSCEPTIBILITY; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNITY; INFECTION; IRIDOCYCLITIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUTH LESION; PATHOGENESIS; POSTERIOR EYE CHAMBER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SKIN DEFECT; SYSTEMIC VASCULITIS; VASCULAR LESION;

BEHCET SYNDROME; HLA-B ANTIGENS; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX;

EID: 38549120095     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.1080/08820530701745264     Document Type: Review

References (64)

1. Devlin T, Gray L, Allen NB, et al. Neuro-Behcet's disease: Factors hampering proper diagnosis. Neurology 1995; 45:1754-7.
2. Chajek T, Fainaru M. Behcet's disease: Report of 41 cases and review of the literature. Medicine 1975; 54:179-96.
3. Yurdakul S, Gunaydin I, Tuzun Y, et al. The prevalence of Behcet's syndrome in a rural area in Northern Turkey. J Rheumatol 1988; 15:820-2.
4. Yamamoto S, Toyokawa H, Matsubara J. A nation-wide survey of Behcet's disease in Japan: 1. Epidemiological survey. Jpn J Ophthalmol 1974; 18:282-90.
5. Foster CS, Baer JC, Raizman MB. 1991. Therapeutic responses to systemic immunosuppressive chemotherapy agents in patients with Behcet's syndrome affecting the eyes. In J.D. O'Duffy, E. Kokman (eds.), Behcet's Disease: Basic and Clinical Aspects pp. 581-588, New York: Marcel Dekker.
6. O'Duffy JD, Taswell HF, Elvebeck LR. HLA antigens in Behcet's disease. J Rheumatol 1976; 3:1-3.
7. Yazici H, Chamberlain MA, Schreuder I, et al. HLA antigens in Behcet's disease: A reappraisal by a comparative study of Turkish and British patients. Ann Rheum Dis 1980; 39:344-8.
8. Behcet's Disease Research Committee of Japan. Behcet's disease: Guide to diagnosis of Behcet's disease. Jpn J Ophthalmol 1974; 18:291-4.
9. International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet 1990; 335:1078-80.
10. Ferraz MB, Walter SD, Heymann R, Atra E. Sensitivity and specificity of different diagnostic criteria for Behcet's disease according to the latent class approach. Br J Rheumatol 1995; 34:932-5.
11. O'Neil TW, Rigby AS, Silman AJ, Barnes C. Validation of the International Study Group criteria for Behcet's disease. Br J Rheumatol 1994; 33:115-7.
12. Mishima S, Masuda K, Izawa Y, et al. Behcet's disease in Japan: Ophthalmological aspects. Trans Am Ophthalmol Soc 1979; 77:225-79.
13. Kurumety U, Okada AA, Usui M, Rao NA. 1999. Behcet's syndrome. In M. Yanoff, J.S. Duker (eds.), Ophthalmology pp. 1-4. London: Mosby.
14. Cohen S, Kremer I, Tiqva P. Bilateral corneal immune ring opacity in Behcet's syndrome. Arch Ophthalmol 1991; 109:324-5.
15. Ehrlich GE. Vasculitis in Behcet's disease. Int Rev Immunol 1997; 14:81-8.
16. Evereklioglu C. Current concepts in the etiology and treatment of Behcet disease. Surv Ophthalmol 2005; 50:297-350.
17. Atmaca LS, Batioglu F, Idil A. Retinal and disc neovascularization in Behcet's disease and efficacy of laser photocoagulation. Graefes Arch Clin Exp Ophthalmol 1996; 234:94-9.
18. Atmaca LS. Fundus changes associated with Behcet's disease. Graefes Arch Clin Exp Ophthalmol 1989; 227:340-4.
19. Wolf SM, Schotland DL, Phillips LL. Involvement of nervous system in Behcet's syndrome. Arch Neurol 1965; 12:315-25.
20. James DG, Spiteri MA. Behcet's disease. Ophthalmology 1982; 89:1279-84.
21. Pamir MN, Kansu T, Erbengi A, Zileli T. Papilledema in Behcet's syndrome. Arch Neurol 1981; 38:643-5.
22. Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behcet's syndrome: A 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine 2003; 82:60-76.
23. Elgin U, Berker N, Batman A. Incidence of secondary glaucoma in Behcet disease. J Glaucoma 2004; 13:441-4.
24. Stewart JAB. Genetic analysis of families if patients with Behcet's syndrome: Data incompatible with autosomal recessive inheritance. Ann Rheum Dis 1986; 45:265-8.
25. Zouboulis CC. Epidemiology of Adamantiades-Behcet's disease. Ann Med Intern 1999; 150:488-98.
26. Zouboulis CC, Kotter I, Djawari D, et al. Epidemiological features of Adamantiades-Behcet's disease in Germany and Europe. Yonsei Med J 1997; 38:411-22.
27. Hamuryudan V, Yurdakul S, Ozbakir F, et al. Monozygotic twins concordant for Behcet's syndrome. Arthritis Rheum 1991; 34:1071-2.
28. Mason RM, Barnes CG. Behcet's syndrome with arthritis. Ann Rheum Dis 1969; 28:95-103.
29. Aoki K, Ohno S, Ohguchi M, Sugiura S. Familial Behcet's disease. Jpn J Clin Ophthalmol 1978; 22:72-5.
30. Fresko I, Soy M, Hamuryudan V, et al. Genetic anticipation in Behcet's disease. Ann Rheum Dis 1998; 57:45-8.
31. Verity DH, Marr JE, Ohno S, et al: Behcet's disease, the Silk Road, and HLA-B51: Historical and geographical perspectives. Tissue Antigens 1999; 54:213-20.
32. Boyer G, Templin D, Bowler A, et al. Class I HLA antigens in sponylarthropathy: Observations in Alaskan Eskimo patients and controls. J Rheumatol 1997; 24:500-6.
33. Ohno S, Ohguchi M, Hirose S, et al. Close association of HLA-Bw51 with Behcet's disease. Arch Ophthalmol 1982; 100:1455-8.
34. Ohno, S. 1986. Behcet's disease in the world. In T. Lehner, C.G. Barnes (eds.), Recent Advances in Behcet's Disease pp. 181-186. London: Royal Society of Medicine Services.
35. Arayssi T, Hamdan A. New insights into the pathogenesis and therapy of Behcet's disease. Curr Opin Pharmacol 2004; 4:183-8.
36. Sano K, Yabuki K, Imagawa Y, et al. The absence of disease-specific polymorphisms within the HLA-B51 gene that is the susceptible locus for Behcet's disease. Tissue Antigens 2001; 58:77-82.
37. Mizuki N, Ohno S, Sato T, et al. Microsatellite polymorphism between the tumor necrosis factor and the HLA-B genes in Behcet's disease. Hum Immunol 1995; 43:129-35.
38. Muzuki N, Ota M, Kimura S, et al. Triplet repeat polymorphism in the transmembrane region of the MICA gene: A strong association of six GCT repetitions with Behcet's disease. Proc Natl Acad Sci USA 1997; 94:1298-303.
39. Groh V, Bahram S, Bauer S, et al. Cell stress- regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 1996; 93:12445-50.
40. Zouboulis CC, May T. Pathogenesis of Admantiades-Behcet's disease. Med Microbiol Immunol 2003; 192:149-55.
41. Park SH, Park KS, Seo YI, et al. Association of MICA polymorphism with HLA-B51 and disease severity in Korean patients with Behcet's disease. J Korea Med Sci 2002; 17:366-70.
42. Kimura T, Goto K, Yabuki K, et al. Microsatellite polymorphism within the MICB gene among Japanese patients with Behcet's disease. Hum Immunol 1998; 59:500-2.
43. Wallace GR, Verity DH, Delamaine LJ, et al. Association of MICA alleles with Behcet's disease. Immunogenetics 1999; 49:613-7.
44. Lee EB, Kim JY, Lee YJ, et al. TNF and TNF receptor polymorphisms in Korean Behcet's disease patients. Hum Immunol 2003; 64:614-20.
45. Gul A, Hajeer AH, Worthington J, et al. Linkage mapping of a novel susceptibility locus for Behcet's disease to chromosome 6p22-23. Arthritis Rheum 2001; 44:2693-6.
46. Karasneh J, Hajeer AH, Barrett J, et al. Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Behcet's disease. Rheumatology (Oxford) 2003; 42:860-4.
47. Hirohata S, Kikuchi H, et al. Behcet's disease. Arthritis Res Ther 2003; 5:139-46.
48. Zierhut M, Mizuki N, Ohno S, et al. Immunology and functional genomics of Behcet's disease. Cell Mol Life Sci 2003; 60:1903-22.
49. Kaneoka H, Furukawa H, Takeno, M, et al. 1993. HLA-B51 involved in the hyperfunction of peripheral blood neutrophils from patients Behcet's disease. In B. Wechsler, P. Godeau (eds.), Behcet's Disease pp. 29-32. Amsterdam: Excerpta Medica.
50. Takeno M, Kariyone A, Yamashita N, et al. Excessive function of peripheral blood neutrophils from patients with Behcet's disease and from HLA-B51 transgenic mice. Arthritis Rheum 1995; 38:426-33.
51. Hammer RE, Maika SD, Richardson JA, et al. Spontaneous inflammatory disease I transgenic rats expressing HLA-B27 and human beta 2m: An animal model of HLA-B27-associated human disorders. Cell 1990; 63:1099-1112.
52. Mizuki N, Inoko H, Mizuki N, et al. Human leukocyte antigen serologic and DNA typing of Behcet's disease and its primary association with B51. Invest Ophthalmol Vis Sci 1992; 33:3332-40.
53. Saper MA, Bjorkman PJ, Wiley DC. Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 A resolution. J Mol Biol 1991; 219:277-319.
54. Fremont DH, Masazumi M, Stura EA, et al. Emerging principles for the recognition of peptide antigens by MHC class I molecules. Science 1992; 257:919-27.
55. Emmi L, Brugnolo F, Salvati G, Marchione T. Immunopathological aspects of Behcet's disease. Clin Exp Rheumatol 1995; 13:687-91.
56. Inoue C, Itoh R, Kawa Y, Mizoguchi M. Pathogenesis of mucocutaneous lesions in Behcet's disease. J Dermatol 1994; 21:474-80.
57. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000; 130:492-513.
58. Biswas, J, Rao NA. 1994. Management of intraocular inflammation. In S.J. Ryan (ed.), Retina, vol. 2, pp. 1061-1069. St. Louis: Mosby Year Book.
59. Mamo JG. The rate of visual loss in Behcet's disease. Arch Ophthalmol 1970;84:451-2.
60. Raynor A, Askari AD. Behcet's disease and treatment with colchicine. J Am Acad Dermatol 1980; 2:396-400.
61. Oniki S, Kurakazu K, Kawata K. Immunosuppressive treatment of Behcet's disease with cyclophosphamide. Jpn J Ophthalmol 1976; 20:32-40.
62. Tessler HH, Jennings T. High-dose short term chlorambucil for intractable sympathetic ophthalmia and Behcet's disease. Br J Ophthalmol 1990; 74:353-7.
63. Nussenblatt RB, Palestine AG, Chan CC. Cyclosporin therapy for uveitis: Long-term follow-up. J Ocul Pharmacol 1985; 1:369-82.
64. Colvard DM, Robertson DM, O'Duffy JD. The ocular manifestations of Behcet's disease. Arch Ophthalmol 1977; 95:1813-7.